Discovery of a novel RSK2 inhibitor for the treatment of metastatic pancreatic cancer
{{output}}
Pancreatic cancer is among the most lethal malignancies, with a five-year survival rate of only 6%. For patients with metastatic disease, current treatments extend median survival by merely four months. This study addresses the urgent need for targeted therapi... ...
